Patents by Inventor Andreas Meinke

Andreas Meinke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN METAPNEUMO VIRUS VACCINE
    Publication number: 20240181034
    Abstract: The present invention relates to a vaccine composition for preventing and/or treating a respiratory system infection such as a human metapneumovirus infection of the respiratory system. This vaccine composition comprises one, two or more modified human metapneumovirus (hMPV) F proteins or variants thereof provided in a pre-fusion -fusion conformation form.
    Type: Application
    Filed: April 8, 2022
    Publication date: June 6, 2024
    Applicant: Valneva SE
    Inventors: Urban Lundberg, Andreas Meinke, Fabien Perugi
  • SUBUNIT VACCINE FOR TREATMENT OR PREVENTION OF A RESPIRATORY TRACT INFECTION
    Publication number: 20240067681
    Abstract: The present invention relates to modified hMPV F proteins stabilized in the pre-fusion conformation as vaccine candidates.
    Type: Application
    Filed: October 24, 2023
    Publication date: February 29, 2024
    Applicant: Valneva SE
    Inventors: Fabien Perugi, Klaus Schwamborn, Wolfgang Schüler, Urban Lundberg, Andreas Meinke
  • MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
    Publication number: 20230295245
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: September 14, 2022
    Publication date: September 21, 2023
    Applicant: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS COMPRISING IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NP3
    Publication number: 20230293661
    Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2022
    Publication date: September 21, 2023
    Applicant: Valneva SE
    Inventors: Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenfuhr, Jurgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
  • CpG-adjuvanted SARS-CoV-2 virus vaccine
    Patent number: 11684669
    Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: June 27, 2023
    Assignees: Valneva Austria GmbH, Dynavax Technologies Corporation
    Inventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen, Jürgen Heindl-Wruss
  • MULTIVALENT OSPA POLYPEPTIDES AND METHODS AND USES RELATING THERETO
    Publication number: 20230151063
    Abstract: The present invention relates to an immunogenic polypeptide, a nucleic acid encoding the same, a pharmaceutical composition comprising the same and the immunogenic polypeptide, nucleic acid or pharmaceutical composition for use as a medicament, particularly a vaccine, or for use in a method of treating or preventing a Borrelia infection.
    Type: Application
    Filed: April 13, 2018
    Publication date: May 18, 2023
    Applicant: Valneva Austria GmbH
    Inventors: Urban Lundberg, Andreas Meinke, Abhijeet Nayak, Wolfgang Schüler
  • CORONAVIRUS VACCINES COMPRISING A TLR9 AGONIST
    Publication number: 20230092650
    Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guano sine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.
    Type: Application
    Filed: March 1, 2021
    Publication date: March 23, 2023
    Applicants: Dynavax Technologies Corporation, Valneva Austria GmbH
    Inventors: John D. Campbell, Robert S. Janssen, David Novack, Christian Taucher, Christoph Reinisch, Andreas Meinke, Michael Möhlen, Robert Schlegl, Jürgen Heindl-Wruss
  • CpG-ADJUVANTED SARS-CoV-2 VIRUS VACCINE
    Publication number: 20230038284
    Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Application
    Filed: September 10, 2021
    Publication date: February 9, 2023
    Applicants: Valneva Austria GmbH, Dynavax Technologies Corporation
    Inventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen
  • Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus CHIKV-Delta5nsP3
    Patent number: 11484587
    Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: November 1, 2022
    Assignee: Valneva SE
    Inventors: Andrea Fritzer, Andreas Meinke, Urban Lunberg, Mario Nebenfuhr, Jurgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 11466058
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: October 11, 2022
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • A SUBUNIT VACCINE FOR TREATMENT OR PREVENTION OF A RESPIRATORY TRACT INFECTION
    Publication number: 20220185847
    Abstract: The present invention relates to modified metapneumovirus (hMPV) F proteins, stabilized in the pre-fusion conformation. It also relates to immunogenic compositions (vaccines) comprising these proteins for preventing and/or treating human subjects against respiratory tract infections.
    Type: Application
    Filed: May 19, 2020
    Publication date: June 16, 2022
    Applicant: Valneva SE
    Inventors: Fabien Perugi, Klaus Schwamborn, Wolfgang Schüler, Urban Lundberg, Andreas Meinke
  • MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
    Publication number: 20220185851
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: November 2, 2021
    Publication date: June 16, 2022
    Applicant: Valneva Austria GmbH
    Inventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
  • Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-Delta5NP3
    Patent number: 11357846
    Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: June 14, 2022
    Assignee: Valneva SE
    Inventors: Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenführ, Jürgen Heindl-Wruss, Robert Schiegl, Arnaud Leon
  • METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS COMPRISING IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NP3
    Publication number: 20220016230
    Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
    Type: Application
    Filed: August 20, 2021
    Publication date: January 20, 2022
    Applicant: Valneva SE
    Inventors: Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenführ, Jürgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 11208439
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: December 28, 2021
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
  • METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS COMPRISING IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NSP3
    Publication number: 20210322534
    Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 19, 2018
    Publication date: October 21, 2021
    Inventors: Andrea Fritzer, Andreas Meinke, Urban Lunberg, Mario Nebenfuhr, Jurgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
  • MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
    Publication number: 20200239525
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: December 4, 2019
    Publication date: July 30, 2020
    Applicant: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 10544194
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 28, 2020
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
    Publication number: 20180327460
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: February 27, 2018
    Publication date: November 15, 2018
    Applicant: Valneva Austria GmbH
    Inventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 9926343
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: March 27, 2018
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel